Pharma Pricing Under Pressure: U.S. Reforms and Potential Implications for the EU Industry

• Comparative overview of pharmaceutical pricing between the U.S. and Europe
• MS/Medicare negotiations and the potential implications of the introduced MFN pricing model
• Proposed U.S. reform initiatives: price referencing and new tariffs on pharmaceuticals
• Strategic impacts on the European pharmaceutical industry, payers, and patients

Who should attend

• Market Access
• Pricing & Reimbursement
• Health Economics
• International Strategy and Business Development

This seminar offers an overview of current transatlantic developments in pharmaceutical pricing. Participants will gain insights into key differences between U.S. and European pricing structures, with a particular focus on U.S. reforms and their global repercussions. Special attention will be paid to CMS/Medicare negotiation mechanisms, the implications of the introduced MFN pricing model, and the new U.S. tariffs on pharmaceuticals.

The seminar will conclude with an outlook on potential implications for the European pharmaceutical landscape, including potential consequences for manufacturers, payers, and patients.

• Gain early insight into policy shifts that could reshape global pharmaceutical markets.
• Understand the legal and commercial risks posed by U.S. price control initiatives and trade measures.
• Stay informed on how U.S. price negotiations and tariff policies may influence EU pricing strategies and export compliance.